(Q24802683)

1

0 references

S J Cotler

2

0 references

G Banaad-Omiotek

3

0 references

R A McNutt

4

0 references

M D Brown

5

0 references

S Cotler

6

0 references

D M Jensen

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7

0 references

language of work or name

English

0 references

publication date

2001

0 references

published in

BMC Gastroenterology

0 references

volume

1

0 references

issue

1

0 references

page(s)

6

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Measurement of health state utilities for economic appraisal

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Utility approach to measuring health-related quality of life

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Health profile preferences of hepatitis C patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Hepatitis C: the clinical spectrum of disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=37537

Clinical outcomes after transfusion-associated hepatitis C.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

Current practice patterns of primary care physicians in the management of patients with hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6

Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-6